
Ahmad Najem

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7482868/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Robust gene expression programs underlie recurrent cell states and phenotype switching in melanoma. Nature Cell Biology, 2020, 22, 986-998.	10.3	148
2	PRIMA-1 and PRIMA-1Met (APR-246): From Mutant/Wild Type p53 Reactivation to Unexpected Mechanisms Underlying Their Potent Anti-Tumor Effect in Combinatorial Therapies. Cancers, 2017, 9, 172.	3.7	91
3	p53 Reactivation by PRIMA-1Met (APR-246) sensitises V600E/KBRAF melanoma to vemurafenib. European Journal of Cancer, 2016, 55, 98-110.	2.8	48
4	P53 and MITF/Bcl-2 identified as key pathways in the acquired resistance of NRAS-mutant melanoma to MEK inhibition. European Journal of Cancer, 2017, 83, 154-165.	2.8	42
5	Targeting prohibitin with small molecules to promote melanogenesis and apoptosis in melanoma cells. European Journal of Medicinal Chemistry, 2018, 155, 880-888.	5.5	28
6	New Drug Combination Strategies in Melanoma: Current Status and Future DirectionsNew Drug Combination Strategies in Melanoma: Current Status and Future Directions. Anticancer Research, 2017, 37, 5941-5953.	1.1	27
7	RTK Inhibitors in Melanoma: From Bench to Bedside. Cancers, 2021, 13, 1685.	3.7	26
8	The Benefit of Reactivating p53 under MAPK Inhibition on the Efficacy of Radiotherapy in Melanoma. Cancers, 2019, 11, 1093.	3.7	18
9	Acquired resistance to BRAFi reverses senescence-like phenotype in mutant BRAF melanoma. Oncotarget, 2018, 9, 31888-31903.	1.8	18
10	Kinome Profiling to Predict Sensitivity to MAPK Inhibition in Melanoma and to Provide New Insights into Intrinsic and Acquired Mechanism of Resistance. Cancers, 2020, 12, 512.	3.7	15
11	Metabolic Reprogramming in Metastatic Melanoma with Acquired Resistance to Targeted Therapies: Integrative Metabolomic and Proteomic Analysis. Cancers, 2020, 12, 1323.	3.7	13
12	Understanding Molecular Mechanisms of Phenotype Switching and Crosstalk with TME to Reveal New Vulnerabilities of Melanoma. Cells, 2022, 11, 1157.	4.1	12
13	Toad Venom Antiproliferative Activities on Metastatic Melanoma: Bio-Guided Fractionation and Screening of the Compounds of Two Different Venoms. Biology, 2020, 9, 218.	2.8	9
14	Tyrosine-Dependent Phenotype Switching Occurs Early in Many Primary Melanoma Cultures Limiting Their Translational Value. Frontiers in Oncology, 2021, 11, 780654.	2.8	7
15	Dasatinib Stimulates Its Own Mechanism of Resistance by Activating a CRTC3/MITF/Bcl-2 Pathway in Melanoma with Mutant or Amplified c-Kit. Molecular Cancer Research, 2021, 19, 1221-1233.	3.4	3